TAPAZOLE (methimazole) by Pfizer is thyroid hormone synthesis inhibitors [moa]. First approved in 1950.
Drug data last refreshed 3h ago · AI intelligence enriched 1w ago
TAPAZOLE (methimazole) is an oral small-molecule thyroid hormone synthesis inhibitor approved in 1950 for hyperthyroidism management. It blocks thyroid peroxidase enzyme activity, reducing production of T3 and T4 hormones in patients with Graves' disease and toxic nodular goiter. The drug is a foundational antithyroid agent used as first-line therapy in many hyperthyroid patients.
As a mature asset approaching loss of exclusivity, the TAPAZOLE team is likely focused on lifecycle management and defending market position against generic competition rather than growth initiatives.
Thyroid Hormone Synthesis Inhibitors
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
TAPAZOLE offers career opportunities primarily in defensive commercial roles (pricing, reimbursement, generic competition strategy) rather than growth-oriented positions. Working on a mature, approaching-LOE asset provides solid foundational pharmaceutical experience but limited exposure to product lifecycle innovation or market expansion.
Worked on TAPAZOLE at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.